Nevro (NYSE:NVRO) Upgraded at Jefferies Financial Group

Jefferies Financial Group upgraded shares of Nevro (NYSE:NVRO) from an underperform rating to a hold rating in a research report sent to investors on Monday morning, MarketBeat Ratings reports. Jefferies Financial Group currently has $5.85 price target on the medical equipment provider’s stock, up from their prior price target of $4.50.

NVRO has been the topic of a number of other reports. Truist Financial decreased their price objective on shares of Nevro from $7.00 to $4.70 and set a “hold” rating on the stock in a research note on Wednesday, December 18th. StockNews.com raised shares of Nevro from a “sell” rating to a “hold” rating in a research note on Tuesday, November 19th. Robert W. Baird boosted their target price on shares of Nevro from $5.00 to $6.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 12th. Citigroup decreased their target price on shares of Nevro from $6.00 to $5.00 and set a “neutral” rating on the stock in a research note on Wednesday, December 11th. Finally, JMP Securities reaffirmed a “market perform” rating on shares of Nevro in a research note on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $6.43.

Nevro Price Performance

Shares of NVRO opened at $5.72 on Monday. Nevro has a 12 month low of $3.16 and a 12 month high of $17.63. The firm’s 50 day moving average is $4.35 and its 200-day moving average is $5.09. The stock has a market capitalization of $214.33 million, a PE ratio of -3.03 and a beta of 0.91. The company has a current ratio of 5.02, a quick ratio of 3.76 and a debt-to-equity ratio of 0.67.

Nevro (NYSE:NVRO) last announced its quarterly earnings data on Monday, November 11th. The medical equipment provider reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.40. The business had revenue of $96.60 million for the quarter, compared to analysts’ expectations of $93.09 million. Nevro had a negative net margin of 16.54% and a negative return on equity of 23.52%. The firm’s quarterly revenue was down 7.0% compared to the same quarter last year. During the same period last year, the firm posted ($0.65) earnings per share. Equities research analysts forecast that Nevro will post -2.43 EPS for the current year.

Institutional Investors Weigh In On Nevro

Several hedge funds and other institutional investors have recently bought and sold shares of NVRO. Amundi bought a new stake in Nevro in the 4th quarter worth about $30,000. Headlands Technologies LLC bought a new stake in Nevro in the 4th quarter worth about $45,000. Ieq Capital LLC bought a new stake in Nevro in the 4th quarter worth about $46,000. Virtu Financial LLC bought a new stake in Nevro in the 3rd quarter worth about $63,000. Finally, SG Americas Securities LLC grew its position in Nevro by 34.6% in the 4th quarter. SG Americas Securities LLC now owns 17,126 shares of the medical equipment provider’s stock worth $64,000 after purchasing an additional 4,406 shares in the last quarter. 95.52% of the stock is owned by institutional investors.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.